Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Shares Issued: 2010-2025

Historic Shares Issued for Altimmune (ALT) over the last 14 years, with Sep 2025 value amounting to $39.5 million.

  • Altimmune's Shares Issued rose 28329.50% to $39.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $121.7 million, marking a year-over-year increase of 14121.50%. This contributed to the annual value of $10.0 million for FY2024, which is 88.46% down from last year.
  • As of Q3 2025, Altimmune's Shares Issued stood at $39.5 million, which was up 4.48% from $37.8 million recorded in Q2 2025.
  • Over the past 5 years, Altimmune's Shares Issued peaked at $39.5 million during Q3 2025, and registered a low of $38,000 during Q2 2024.
  • In the last 3 years, Altimmune's Shares Issued had a median value of $5.1 million in 2023 and averaged $13.6 million.
  • As far as peak fluctuations go, Altimmune's Shares Issued plummeted by 99.71% in 2024, and later spiked by 99,434.21% in 2025.
  • Over the past 5 years, Altimmune's Shares Issued (Quarterly) stood at $12.5 million in 2021, then grew by 17.43% to $31.8 million in 2022, then tumbled by 98.40% to $510,000 in 2023, then crashed by 72.75% to $9.6 million in 2024, then spiked by 28,329.50% to $39.5 million in 2025.
  • Its Shares Issued was $39.5 million in Q3 2025, compared to $37.8 million in Q2 2025 and $34.7 million in Q1 2025.